The Folinic acid market is poised for continued growth in 2024, driven by its essential role in oncology, the treatment of folate deficiencies, and its increasing use in various medical therapies. Folinic acid, also known as leucovorin, has proven to be an effective agent in reducing the toxic effects of chemotherapy drugs, particularly methotrexate, and plays a key role in folate supplementation.